Decanoic Acid–Arginine Lamellar Complexes Against Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of antibiotic-resistant pathogens, particularly gram-positive bacteria like MRSA and VRE, poses a significant challenge in treating skin infections and infections associated with surgical or traumatic wounds, which can lead to severe health issues such as sepsis and death. Additionally, the rise of multi-resistant infections and their link to cancer progression necessitates new therapeutic methods with high efficacy and low side-effects.
Innovation Solution
Compositions comprising fatty acids, such as undecylenic acid and decanoic acid, combined with amino acids like L-arginine, are developed to form therapeutic complexes that exhibit anti-pathogenic and anti-cancer effects. These compositions are formulated within specific molar ratios (1:0.6 to 1:1.6) without the need for excipients like cetyl alcohol, forming lamellar supramolecular structures for enhanced stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then initial treatment effectiveness is improved, but antibiotic resistance develops leading to treatment failure
Solution Approach 1:
The patent changes the chemical parameters by using fatty acids with specific chain lengths (C6-C12) and specific amino acids (arginine, lysine, histidine) in defined molar ratios (1:0.6 to 1:1.6). This parameter optimization creates compositions that achieve bactericidal activity through alternative mechanisms that do not induce resistance like traditional antibiotics
Solution Approach 2:
The patent combines fatty acids and amino acids into composite therapeutic compositions. These composite materials work synergistically to disrupt bacterial cell membranes and inhibit pathogen growth without relying on antibiotic mechanisms, thereby avoiding resistance development while maintaining treatment effectiveness
2Reliability
If fatty acid and amino acid compositions are formulated within specific molar ratios, then therapeutic efficacy is improved, but formulation complexity increases
Solution Approach 1:
The patent establishes specific molar ratio parameters (1:0.6 to 1:1.6) for fatty acid to amino acid combinations to optimize therapeutic efficacy. While this introduces formulation parameters, the patent simplifies the overall system by eliminating excipients like cetyl alcohol and focusing on active ingredient ratios, making the formulation process more controllable and reproducible
3Object-affected harmful factors
If excipients like cetyl alcohol are eliminated from formulations, then safety and reduced toxicity are improved, but formulation stability may worsen
Solution Approach 1:
The patent removes excipients like cetyl alcohol from the formulation to eliminate potential toxicity and harmful effects. The stability previously provided by these excipients is replaced by optimizing the interactions between the active ingredients (fatty acids and amino acids) themselves, creating a cleaner, safer formulation that maintains stability through molecular compatibility rather than excipient mediation
Solution Approach 2:
The fatty acid and amino acid components serve their own stabilization functions without requiring external excipients. The amino acids stabilize the fatty acid structures and maintain formulation integrity through their inherent chemical properties, making the system self-sufficient and eliminating the need for potentially toxic stabilizing agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions demonstrate potent antibacterial, antiviral, and anticancer activities against both gram-positive and gram-negative bacteria, fungi, and viruses, with improved stability and reduced toxicity, offering effective treatment options for infections and cancers.
Implementation Method 1
These compositions are formulated within specific molar ratios (1:0.6 to 1:1.6) without the need for excipients like cetyl alcohol, forming lamellar supramolecular structures for enhanced stability and efficacy
Data Source
AI summary
Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. In particular, described herein are compositions of decanoic acid:Arginine in which the decanoic acid and Arginine for a complex having a lamellar supramolecular structure.